TGFBR2 and central nervous system cancer: Emerging evidence suggests TGFBR2 signaling can support oncogenic mechanisms in glioma cells, including resistance to therapy and maintenance of the stem cell phenotype,4–8 and blocking these signaling in gliomas may offer therapeutic advantages in the context of recurrent disease.4,7